Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-08

Study Completion Date

2024-12-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of HIV and HSV sexual infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

NCT04047420

HIV Infections

COMPLETED PHASE1

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418

HIV Prevention

COMPLETED PHASE1

Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV

NCT00441298

HIV Infections

COMPLETED PHASE2

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

NCT00705679

HIV Infections

COMPLETED PHASE2

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

NCT03279120

Anti-Infective Agents Anti-Retroviral Agents Contraceptive Usage

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will be enrolled across three sites, in USA, Kenya, and South Africa, approximately 20 per site. Participants will be randomized (1:1) to receive either a placebo or TAF/EVG vaginal insert as well as be randomized (1:1:1) to 3 different tissue sampling time points post-treatment (24hr, 48hr and 72hr after the last dose). Participants will be asked to complete 8 study visits with clinical and behavioral evaluations, and a subset will complete an in-depth interview to assess acceptability of vaginal insert use.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety Issues

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, Placebo-Controlled, Double-Blind

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

TAF/EVG (20/16mg) vaginal insert

Group Type EXPERIMENTAL

TAF/EVG vaginal insert

Intervention Type DRUG

vaginal insert applied daily for 3 days then every other day for 14 days

Placebo

Matching placebo insert

Group Type PLACEBO_COMPARATOR

Matching Placebo vaginal insert

Intervention Type DRUG

vaginal insert applied daily for 3 days then every other day for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAF/EVG vaginal insert

vaginal insert applied daily for 3 days then every other day for 14 days

Intervention Type DRUG

Matching Placebo vaginal insert

vaginal insert applied daily for 3 days then every other day for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 18 to 50 years (inclusive) at Screening.
2. Assigned female sex at birth.
3. Able and willing to provide written informed consent to be screened for and enrolled in MATRIX-001 in one of the study languages (as specified in site SOP).
4. General good health (by volunteer history) without any evidence of clinically significant systemic disease (as determined by Investigator of Record \[IoR\] or designee).
5. Has had vaginal sex and has an intact uterus and cervix.
6. Has a regular and/or predictable bleeding pattern based on the opinion of the investigator, or is oligomenorrheic or amenorrhoeic.
7. HIV-uninfected based on testing performed at Screening and Enrollment (per protocol algorithms in Appendix II).
8. Negative urine pregnancy test at Screening and Enrollment.
9. Protected from pregnancy by an effective contraceptive method as confirmed by site SOP; effective methods include:

* minimum of 3 months of use of a combined hormonal contraceptive method (except vaginal rings)
* minimum of 6 months of use of a progestin only contraceptive method or copper IUD
* Sterilization of participant or partner
* Correct and consistent condom use (for US site only)
* Abstinence from penile-vaginal intercourse (for US site only)
10. Participants over the age of 21 (inclusive) must have documentation of a Grade 0 Pap smear within the past 3 years prior to Enrollment, per the Female Genital Grading Table for Use in Microbicide Studies Addendum 1 (Dated November 2007) to the DAIDS Table for Grading Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017, or Grade 1 Pap smear at Screening with no treatment required.
11. Normal cervicovaginal mucosa (as defined in MATRIX-001 Study Specific Procedures \[SSP\] manual).
12. Willing and able to comply with protocol requirements, including abstaining from vaginal activity and product use at specified times.
13. Per participant report, if in a relationship, must be in a mutually monogamous relationship with a partner who is not known to be HIV positive or to currently have an STI.

Exclusion Criteria

1. Per participant report, intends to do any of the following during the study participation period:

* Become pregnant.
* Breastfeed.
* Relocate away from the study site.
* Travel away from the study site for a time period that would interfere with product resupply and/or study participation.
2. Currently breastfeeding.
3. Positive HIV test at Screening or Enrollment.
4. History of sensitivity/allergy to any component of the study product, topical anesthetic, cellulose based thrombogenic material, or to both silver nitrate and Monsel's solution.
5. Positive test for Trichomonas vaginalis (TV), Neisseria gonorrhea (GC), Chlamydia trachomatis (CT), Treponema pallidum (Syphilis), or Hepatitis B surface antigen (HBsAg) at Screening or (per participant report) treated for GC, CT, TV, HBsAg or syphilis in the past 12 months.
6. Chronic or acute vulvar, vaginal or cervical symptoms (pain, irritation, spotting/bleeding other than what would be expected from contraceptive use, discharge, etc.).
7. Known bleeding/clotting disorder, including use of anti-coagulation.
8. Need for continued use of any contraindicated concomitant medications (as listed in Appendix III).
9. Participation in any other trial with use of an investigational drug/device within the last 30 days or planned participation in any other investigational trial with use of a drug/device during the study.
10. Participants who previously received an HIV vaccine or HIV broadly neutralizing antibody (bNAb) are not eligible. Individuals may be eligible if they participated in an HIV vaccine or bNAb study but have documentation that they did not receive active product (e.g., placebo recipients).
11. Prior use of PEP or oral PrEP (including FTC/TDF) in the past 4 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
12. Grade 2 or higher pelvic finding or laboratory abnormality, per the DAIDS Table for Grading Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 and/or Addenda 1 (Female Genital Grading Tables for Use in Microbicide Studies \[Dated November 2007\]) or clinically significant laboratory abnormality as determined by the clinician.
13. Use of any of the following in the past 12 months: stimulants (cocaine \[including crack\], methamphetamine, or non-physician prescribed pharmaceutical-grade stimulants), or inhaled nitrates, or illicit injection drug use of any kind.
14. Has any other condition that, based on the opinion of the IoR or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes